Treatment decisions for advanced breast cancer are guided by the expression of three major therapeutic targets: estrogen receptor-α (ER), progesterone receptor (PR) and human epidermal growth factor receptor-2 (HER2) [3]. Here, ERBB2 is linked to breast cancer.